OTCMKTS:HYPMY Hypermarcas (HYPMY) Stock Price, News & Analysis $4.86 +0.06 (+1.15%) As of 05/8/2026 03:06 PM Eastern Add Compare Share Share Stock Analysis Stock AnalysisAnalyst ForecastsChartDividendEarningsHeadlinesSEC FilingsShort InterestBuy This Stock About Hypermarcas Stock (OTCMKTS:HYPMY) View Price History Chart DataSkip Price History Chart 1 Day 5 Days 30 Days 90 Days 1 Year Advanced 1 Day 1 Day 5 Days 30 Days 90 Days 1 Year Advanced Show volume Show extended hours Get Hypermarcas alerts:Sign Up Key Stats Today's Range$4.85▼$4.8650-Day Range$3.92▼$4.8252-Week Range$3.71▼$5.50Volume4,647 shsAverage Volume28,491 shsMarket Capitalization$3.42 billionP/E Ratio10.12Dividend Yield2.68%Price TargetN/AConsensus RatingBuy Company Overview Hypermarcas S.A. is a Brazil-based consumer health and pharmaceutical company whose shares trade over the counter in the United States under the symbol HYPMY. Founded in the early 2000s and headquartered in Rio de Janeiro, the company operates as a holding group for a broad portfolio of branded products in the healthcare and personal care sectors. Through its various subsidiaries, Hypermarcas develops, manufactures and markets prescription and over-the-counter medications, alongside personal care, baby care, home care and nutritional supplement products. Its pharmaceutical lineup includes analgesics, anti-inflammatories, vitamins and dermatological preparations, while its consumer goods segment encompasses shampoos, soaps, lotions and oral hygiene items under multiple local brands. Primarily focused on the domestic Brazilian market, Hypermarcas has also extended its reach into other Latin American countries via export partnerships and regional distributors. Over the years, the company has grown through acquisitions of smaller domestic drugmakers and consolidation of well-known local brands. Detailed executive leadership information is not widely available in public sources. AI Generated. May Contain Errors. Read More Receive HYPMY Stock News and Ratings via Email Sign-up to receive the latest news and ratings for Hypermarcas and its competitors with MarketBeat's FREE daily newsletter. Submit View SMS TermsSMS is currently available in Australia, Belgium, Canada, France, Germany, Ireland, Italy, New Zealand, the Netherlands, Singapore, South Africa, Spain, Switzerland, the United Kingdom, and the United States. By entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy. HYPMY Stock News HeadlinesHypermarcas (OTCMKTS:HYPMY) Upgraded at Zacks ResearchMay 2, 2026 | americanbankingnews.comHypera S.A. (HYPMY) Q3 2025 Earnings Call TranscriptOctober 29, 2025 | seekingalpha.comRead this or regret it foreverThree Nobel Prize Winners expose this once-in-a-generation wealth shift: “Don’t Say I Didn’t Warn You” Porter Stansberry exposes how the convergence of three immense forces is about to rewrite everything about the American way of life: how you work, save, invest… it’s all about to change.May 10 at 1:00 AM | Porter & Company (Ad)Brazil's Hypera announces new majority stakeholder groupJuly 7, 2025 | reuters.comHypera S.A. (HYPMY) Stock Price, Quote, News & Analysis - Seeking AlphaJune 29, 2025 | seekingalpha.comHypera S.A. credit rating downgraded due to increased leverageApril 9, 2025 | investing.comHypera SA (HYPMY) Q4 2024 Earnings Call Highlights: Navigating Growth and ChallengesMarch 24, 2025 | finance.yahoo.comHypera S.A. Reports 2024 Financial PerformanceMarch 21, 2025 | tipranks.comSee More Headlines HYPMY Stock Analysis - Frequently Asked Questions How have HYPMY shares performed this year? Hypermarcas' stock was trading at $4.1375 on January 1st, 2026. Since then, HYPMY shares have increased by 17.3% and is now trading at $4.8552. How were Hypermarcas' earnings last quarter? Hypermarcas (OTCMKTS:HYPMY) announced its earnings results on Wednesday, April, 29th. The company reported $0.10 EPS for the quarter. The firm earned $383.13 million during the quarter. Hypermarcas had a trailing twelve-month return on equity of 14.08% and a net margin of 19.41%. How do I buy shares of Hypermarcas? Shares of HYPMY stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services. Company Calendar Last Earnings4/29/2026Today5/10/2026Fiscal Year End12/31/2026Get Stock AlertsIndustry, Sector and Symbol Stock ExchangeOTCMKTS SectorMedical Industry MED - DRUGS Sub-IndustryN/A Current SymbolOTCMKTS:HYPMY CIK1486749 Webwww.hyperapharma.com.br Phone55-11-3627-4206FaxN/AEmployees10,481Year Founded2001Profitability EPS (Trailing Twelve Months)$0.48 Trailing P/E Ratio10.12 Forward P/E Ratio9.16 P/E GrowthN/ANet Income$213.10 million Net Margins19.41% Pretax Margin4.04% Return on Equity14.08% Return on Assets6.91% Debt Debt-to-Equity Ratio0.61 Current Ratio1.27 Quick Ratio0.84 Sales & Book Value Annual Sales$1.38 billion Price / Sales2.48 Cash Flow$0.47 per share Price / Cash Flow10.27 Book Value$3.54 per share Price / Book1.37Miscellaneous Outstanding Shares704,010,000Free FloatN/AMarket Cap$3.42 billion OptionableNot Optionable Beta0.73 Social Links The Next 7 Blockbuster Stocks for Growth InvestorsWondering what the next stocks will be that hit it big, with solid fundamentals? Click the link to see which stocks MarketBeat analysts could become the next blockbuster growth stocks.Get This Free Report This page (OTCMKTS:HYPMY) was last updated on 5/10/2026 by MarketBeat.com Staff. From Our PartnersMassive Data Leak Exposes 512,000-Line Code That Could Change Society Forever"You won't believe what I discovered at 4 World Trade Center" When our financial media correspondent travel...Chaikin Analytics | SponsoredThis is the worst news for stocks in 50 yearsGoldman Sachs and Morgan Stanley are issuing a rare warning: what's ahead for U.S. stocks could be the worst e...TradeSmith | SponsoredThe REAL Reason Trump is Invading IranFor a moment… Forget about Trump’s ties to Israel. Forget about reports of Iran’s nuclear program. Be...Banyan Hill Publishing | SponsoredThe NASTY TRUTH about the SpaceX IPOIn nearly every major IPO, roughly 95% of the gains are captured before retail investors can place a trade. It...The Oxford Club | SponsoredRead this or regret it foreverThree Nobel Prize Winners expose this once-in-a-generation wealth shift: “Don’t Say I Didn’t Warn You” P...Porter & Company | Sponsored"Computers are about to become obsolete" - George Gilder. Here’s why.George Gilder predicted the iPhone 16 years early, called Netflix a decade before it dominated streaming, and ...Eagle Publishing | SponsoredLouis Navellier: My #1 AI stock for 2026 (name & ticker inside)Louis Navellier's Stock Grader system helped him flag Nvidia before its 82,000% run and has identified the top...InvestorPlace | SponsoredThe chokepoint supplier behind SpaceX's $1.75 trillion empireMusk needed solar - he acquired SolarCity. Needed data - he bought Twitter. The pattern is clear: when a suppl...Behind the Markets | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added ten stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Hypermarcas Please log in to your account or sign up in order to add this asset to your watchlist. Share Hypermarcas With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In Email Me a Login Link or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
Free HYPMY Stock Alerts